Figure 2
From: The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update
Results from recent clinical trial with inhaled Technosphere insulin plus insulin glargine. (A) Glycosylated hemoglobin (HbA1c) values over 52 weeks for patients who were treated with inhaled Technosphere insulin plus insulin glargine versus patients who were treated with Biaspart insulin by SC; (B) Change in fasting plasma glucose from baseline for two patient groups over 52 weeks (from Reference [36] with Permission).